Magdi Elsallab, MD, PhD

🚨 Exciting News! 🚨 The largest analysis of cell and gene therapy clinical development success probabilities is here! What we did: - Analyzed 900+ cell and gene therapies and 2,500 clinical trials to build 1,900 development programs. Read here onlinelibrary.wiley.com/share/author/H…

Discrepancies in clinical trial evidence reported to the FDA and EMA for cell and gene therapies highlight the need for harmonization in regulatory submissions. ja.ma/421j4Eo

The Hospital Clínic de Barcelona & @MedicalCollege are rethinking how #CAR-T therapies are manufactured. Read our feature on the topic sohoinsider.com/news/spains-mo… @niravshahmd @ElsallabMagdi Leticia Alserawan

@HarvardMIT_CRS Director @ftbourgeois, former CRS fellow @ElsallabMagdi, and former visiting student Sandra Gillner, publish @JAMAInternalMed study comparing evidence submitted to the FDA and EMA for cell and gene therapies. Find the full study here: jamanetwork.com/journals/jamai…

check out Eva Gottwein's new preprint carefully measuring the toxicity of some CRISPRa activation systems. This is an issue today for functional genomics research and potentially for future therapeutics that use synthetic transcriptional activators biorxiv.org/content/10.110…

Preprint alert 🚨 Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐 Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells biorxiv.org/content/10.110… 🧵👇

The FDA has approved the first telomerase inhibitor, imetelstat, to treat myelodysplastic syndromes following an epic journey for the drug, which has been tested in more than 20 trials over the past 20 years in various cancers. Find out more here bit.ly/4ekijKL

Great overview of the cellular immunotherapy landscape.

Happy to see our work on the cover of @BloodJournal! If you haven’t read it yet, check out our study analyzing FDA adverse event reports for second primary malignancies post-CAR T cells: authors.elsevier.com/a/1j5wZ1UYwnBkJ

More momentum on the #POC manufacturing front. Enter, regional blood banks. @GalapagosGlobal @BCAbloodcenters glpg.com/press-releases…

🚀 Join Our Team at Baylor College of Medicine! 🧬 We’re looking for passionate technician to join our lab at @CAGTHouston. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing. Pls RT 🙏 jobs.bcm.edu/job/Research-T…

@carlhjune and I reviewed the current evidence on the potential risk of T-cell lymphoma after #CART immunotherapy. Now online @BCD_AACR !!! @PennMedicine @PennCancer rb.gy/im1r7i

What is the incidence of T-cell malignancies after CAR-T? @ElsallabMagdi, of @MGHCancerCenter, and @EllithiMd, of @UNMC, stopped by BCT to discuss their FAERS database analysis on T-cell malignancies after CAR-T. 📺 Watch here: buff.ly/4aYtiqu

Why can RNA only be linear or circular? It can be branched! We made multi-tailed mRNA, and we had fun! Here is our story led by brilliant graduate student @HongyuChenChem: rdcu.be/dB7ck and his cartoon illustration👇@ChemistryMIT @broadinstitute